MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

MC

445.15

+0.33%↑

SANES

6.915

+0.12%↑

ALV

341.6

-0.23%↓

BNP

75.89

-0.05%↓

BBVA

12.755

-0.7%↓

Search

Sartorius Stedim Biotech.

Deschisă

SectorFinanțe

204.7 0.54

Rezumat

Modificarea prețului

24h

Curent

Minim

201.1

Maxim

207.6

Indicatori cheie

By Trading Economics

Venit

75M

115M

Vânzări

-6.7M

745M

P/E

Medie Sector

92.346

24.617

EPS

1.16

Randament dividend

0.34

Marjă de profit

15.498

Angajați

9,961

EBITDA

124M

256M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+15.15% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

0.34%

4.23%

Următoarele câștiguri

22 iul. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

2.4B

19B

Deschiderea anterioară

204.16

Închiderea anterioară

204.7

Sentimentul știrilor

By Acuity

39%

61%

141 / 538 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Sartorius Stedim Biotech. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 iun. 2025, 23:49 UTC

Câștiguri

Nike Sees Sales Decline Decelerating in 1Q as Turnaround Strategy Plays Out -- 2nd Update

26 iun. 2025, 22:19 UTC

Achiziții, Fuziuni, Preluări

FTC Clears Alimentation Couche-Tard's $1.57 Billion GetGo Acquisition

26 iun. 2025, 21:30 UTC

Câștiguri

Nike 4Q Profit, Revenue Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Câștiguri

Nike 4Q Profit, Revenue Slide as Turnaround Strategy Plays Out

26 iun. 2025, 23:49 UTC

Market Talk

Nikkei May Rise as Fears About Middle East Conflict Ebb -- Market Talk

26 iun. 2025, 23:39 UTC

Market Talk

Gold Edges Lower, Weighed by Stronger-Than-Expected U.S. Data -- Market Talk

26 iun. 2025, 23:34 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: Lease Reset Provides Opportunity for Upgrades, Extensions

26 iun. 2025, 23:33 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: 62 BWP-Owned Bunnings Sites Get Significantly Longer Leases

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers Will No Longer Receive Earnings From BWP Management

26 iun. 2025, 23:32 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Increase BWP Holding to 23.5% From 22.3%

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers: New BWP Units Priced at 9.2% Premium to Last Close

26 iun. 2025, 23:31 UTC

Achiziții, Fuziuni, Preluări

BWP to Pay A$100 Mln Cash, A$42.6 Mln in New Units

26 iun. 2025, 23:30 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers' Bunnings, BWP Trust to Extend and Vary Leases

26 iun. 2025, 23:29 UTC

Achiziții, Fuziuni, Preluări

Wesfarmers to Sell BWP Management to BWP Trust for A$142.6M

26 iun. 2025, 23:19 UTC

Achiziții, Fuziuni, Preluări

Andlauer Healthcare Group: Ontario Superior Court of Justice Issues Final Order Approving Sale to UPS

26 iun. 2025, 22:06 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:15 UTC

Câștiguri

Nike 4Q Profit, Rev Slides as Turnaround Strategy Plays Out -- Update

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: 35 Stores to Be Divested in Accordance With Regulatory Requirements >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: GetGo Will Operate as Separate, Stand-Alone Business Unit, Maintain myPerks Loyalty Program >ATD.T

26 iun. 2025, 21:07 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Buyer Will be Approved by the FTC >ATD.T

26 iun. 2025, 21:07 UTC

Câștiguri

Nike's Earnings Were Ugly. But They're Better Than Feared. -- Barrons.com

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard Agreed to Sell 35 Sites, Including 34 Circle K Locations and One GetGo Property >ATD.T

26 iun. 2025, 21:06 UTC

Achiziții, Fuziuni, Preluări

Couche-Tard: Transaction Is Expected to Close in the Coming Days >ATD.T

26 iun. 2025, 21:06 UTC

Market Talk

Bank of Mexico Seen Likely to Slow Pace of Rate Cuts -- Market Talk

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 21:05 UTC

Achiziții, Fuziuni, Preluări

COUCHE-TARD RECEIVES FTC CLEARANCE TO COMPLETE ACQUISITION OF GETGO CAFÉ + MARKET >ATD.T

26 iun. 2025, 20:52 UTC

Câștiguri

Nike 4Q Profit, Rev Slide as Turnaround Strategy Plays Out

26 iun. 2025, 20:51 UTC

Câștiguri

Correct: Nike 4Q Net $211M, Not $200M >NKE

26 iun. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 iun. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Comparație

Modificare preț

Sartorius Stedim Biotech. Așteptări

Obiectiv de preț

By TipRanks

15.15% sus

Prognoză pe 12 luni

Medie 234.67 EUR  15.15%

Maxim 250 EUR

Minim 210 EUR

În baza a 9 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSartorius Stedim Biotech. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

9 ratings

5

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

202.7 / 211.7Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Strong Bullish Evidence

Sentiment

By Acuity

141 / 538 Clasament în Finanțe

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.